The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1737
ISSUE1737
September 15, 2025
Ceftobiprole Medocaril (Zevtera) — A New Cephalosporin Antibiotic
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Ceftobiprole Medocaril (Zevtera) — A New Cephalosporin Antibiotic
September 15, 2025 (Issue: 1737)
Ceftobiprole medocaril sodium (Zevtera – Innoviva
Specialty Therapeutics), a new IV cephalosporin
antibacterial drug, has been approved by the FDA for
treatment of Staphylococcus aureus bacteremia (SAB),
including right-sided infective...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.